Time of first stool in premature infants: effect of gestational age and illness severity.

OBJECTIVE: To assess the effect of gestational age and illness severity, and the effect of antenatal exposure to magnesium sulfate and glucocorticosteroids, on the timing of the first stool in preterm infants. METHODS: Medical records of all preterm infants (born at < or = 36 weeks of gestational age) admitted to the neonatal intensive care unit at Georgetown University Hospital between April 1993 and March 1994 were reviewed. We studied the time of the first stool in 221 infants after removing from the investigation the 45 infants who met the exclusion criteria. RESULTS: The median age of the infants at the time of the first stool was 18 hours, and 90% of the infants passed stool by 100 hours after birth. Both the gestational age and the illness severity, as measured by the Score for Neonatal Acute Physiology (SNAP), independently correlated with the timing of first stool (r = 0.31 and p < 0.0001 for gestational age; r = 0.33 and p < 0.0001 for SNAP). Of the 221 infants, 172 (78%) passed stool before the initiation of enteral feeding. Antenatal exposure to magnesium sulfate for tocolysis had no effect on the timing of the first stool, whereas infants whose mothers received glucocorticosteroids for enhancing fetal lung maturity passed their first stool significantly earlier than nonexposed infants of identical gestational age (p = 0.005). CONCLUSION: Delayed passage of first stool is a function of both illness severity and gestational immaturity. Antenatal betamethasone exposure leads to earlier stool passage, whereas antenatal exposure to magnesium sulfate does not affect the timing of first stool in premature infants.

Health and neurodevelopmental outcome at 1-year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactant. American Exosurf Neonatal Study Groups I and II.

A three-dose prophylactic regimen of synthetic surfactant replacement has been shown to improve neonatal and 1-year survival rates in infants of 700 to 1100 gm birth weight when compared with a single prophylactic dose. The purpose of this study was to evaluate the growth, development, and late morbidity at 1 year adjusted age among the survivors of the 826 patients enrolled in the protocol. Complete follow-up data were obtained for 75% of the survivors in both groups. Chronic lung disease, need for respiratory support, neurologic disease requiring medication, visual or auditory impairments, and the incidence and severity of retinopathy of prematurity were equivalent in the two groups. The frequency of neurodevelopmental impairment was also comparable in the groups that received one dose versus three doses: moderate to severe cerebral palsy was found in 9% versus 6%, mental retardation assessed by Bayley Scales of Infant Development scores less than 69 was found in 16% vs 14%, and moderate to severe impairments of any kind were found in 33% vs 24%, respectively. Furthermore, the absolute number of impaired survivors was 92 in the three-dose group versus 106 in the one-dose group, despite a higher survival rate in the three-dose group. This study demonstrates that developmental outcomes of infants weighing 700 to 1100 gm who received three prophylactic doses of synthetic surfactant are at least as good as those of infants receiving a single dose, and that improving survival rates of very premature infants with synthetic surfactant does not result in increased numbers of infants with impairments.

Time of first stool in extremely low birth weight (< or = 1000 grams) infants.

The time of first stool was studied in 144 infants with a birth weight of 1000 gm or less. Median age at passage of the first stool was 3 days, and 90% of the infants passed stool by 12 days after birth. There was no relationship between the time of passage of the first stool and either birth weight or gestational age. Of the 114 infants, 88 (77%) passed stool before the initiation of any enteral feeding. The passage of the first stool was delayed in male compared with female infants (p = 0.03).

Postheparin lipolytic activity and Intralipid clearance in very low-birth-weight infants.

The effect of heparin (10 U/kg) on serum lipolytic activity, triglyceride and FFA levels, during four hours infusion of 0.5 gm/kg Intralipid was measured in 18 AGA infants, 25 to 32 weeks' gestational age. PHLA, TG, and FFA were measured at 0, 10, 30, 120, and 240 minutes of infusion of Intralipid, before and following a bolus of 10 U/kg heparin iv. Lipolytic activity, measured by hydrolysis of activated tri-3H-oleate and expressed in mumol FFA released per milliliter serum per hour, was not detected in serum before heparin administration. Ten minutes after heparin administration peak PHLA was significantly higher in infants of 27 to 32 weeks' gestation than in infants of 25 to 26 weeks' gestation. There was no significant difference in peak PHLA between infants of 27 to 28 and 29 to 32 weeks' gestation. PHLA returned to baseline (zero) two hours after heparin administration in all infants. Infants of 25 to 26 weeks' gestational age had significantly higher concentrations of serum triglycerides before and during Intralipid infusion than in infants of 27 to 32 weeks' gestational age. Although there was a transient rise in FFA 10 and 30 minutes after heparin administration, the levels of FFA and triglycerides were not different at the end of infusion with or without heparin in either group, suggesting that a single bolus of heparin has only a transient effect on Intralipid clearance.